- Home
- MKTW vs BOLD Comparison
MKTW vs BOLD Comparison
Compare MKTW & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- BOLD
- Stock Information
- Founded
- MKTW 1999
- BOLD 2018
- Country
- MKTW United States
- BOLD United States
- Employees
- MKTW N/A
- BOLD N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- BOLD
- Sector
- MKTW Technology
- BOLD
- Exchange
- MKTW Nasdaq
- BOLD Nasdaq
- Market Cap
- MKTW 30.3M
- BOLD 30.3M
- IPO Year
- MKTW N/A
- BOLD 2024
- Fundamental
- Price
- MKTW $15.76
- BOLD $1.55
- Analyst Decision
- MKTW
- BOLD Hold
- Analyst Count
- MKTW 0
- BOLD 1
- Target Price
- MKTW N/A
- BOLD N/A
- AVG Volume (30 Days)
- MKTW 28.3K
- BOLD 58.5K
- Earning Date
- MKTW 05-08-2025
- BOLD 05-09-2025
- Dividend Yield
- MKTW 4.68%
- BOLD N/A
- EPS Growth
- MKTW 207.28
- BOLD N/A
- EPS
- MKTW 3.12
- BOLD N/A
- Revenue
- MKTW $383,217,000.00
- BOLD N/A
- Revenue This Year
- MKTW N/A
- BOLD N/A
- Revenue Next Year
- MKTW $0.42
- BOLD N/A
- P/E Ratio
- MKTW $5.06
- BOLD N/A
- Revenue Growth
- MKTW N/A
- BOLD N/A
- 52 Week Low
- MKTW $9.08
- BOLD $1.06
- 52 Week High
- MKTW $33.60
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- MKTW 68.74
- BOLD N/A
- Support Level
- MKTW $13.01
- BOLD N/A
- Resistance Level
- MKTW $16.12
- BOLD N/A
- Average True Range (ATR)
- MKTW 0.90
- BOLD 0.00
- MACD
- MKTW 0.19
- BOLD 0.00
- Stochastic Oscillator
- MKTW 89.63
- BOLD 0.00
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.